Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vebecototumab
- Development stage
- Phase 2
- Lead developer
- Mabwell
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Vebecototumab (MW032) is a humanized IgG1 monoclonal antibody that targets **B7-H3** (CD276), a transmembrane protein belonging to the B7 family of immune checkpoint molecules. B7-H3 is frequently overexpressed in various solid tumors, including high-grade gliomas, and is associated with tumor progression, immune evasion, and poor prognosis. By binding specifically to B7-H3, vebecototumab aims to inhibit tumor growth and potentially enhance anti-tumor immune responses by blocking inhibitory signals to T-cells or mediating antibody-dependent cellular cytotoxicity (ADCC). Developed by **Mabwell (Shanghai) Bioscience**, it is currently being evaluated in Phase 2 clinical trials in China, notably in combination with bevacizumab and re-radiotherapy for the treatment of recurrent high-grade gliomas (WHO grade III-IV).
- Other names
- vebecototumabMW032MW-032MW 032
02
Targets
RANKL (Receptor Activator for Nuclear Factor-kappa B Ligand)B7-H3
Beyond the preview
Go deeper on vebecototumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vebecototumab.